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Abstract 
 
A mathematical model has been developed which describes human cell growth 
in the presence of topotecan (TPT), an anti-cancer agent.  Previously, a model was 
developed for the pharmacokinetics (PK) of TPT; this provided a description of the 
activity of TPT and the subsequent delivery of the active form to the nuclear DNA 
target.  This model is described briefly in this paper.  The development of a new 
pharmacodynamic (PD) model for cell growth, based on a well-known cell cycle 
model is then discussed.  The linking of the PK model to the PD model is considered 
with respect to the modulation of cell growth.  Our PK – PD model has good 
agreement with in vitro experimental data.  In a clinical context, it is intended that the 
model will be used for discovering routes for drug resistance and eventually as a tool 
for improving drug treatments for patients. 
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1. Introduction 
 
The development of anti-cancer agents is an expensive and lengthy process. 
The aim is to find and develop agents for drugs which possess one or more 
therapeutic, toxicological and pharmacokinetic properties.  These are initially 
assessed through laboratory-based investigations conducted in vitro to establish proof-
of-principle and subsequently in vivo analyses where the pharmacokinetic (PK) and 
pharmacodynamic (PD) properties are assessed.  During this stage, agents are either 
rejected or developed further through to clinical trials. 
The use of mathematical models which utilise ideas from systems engineering 
to aid this process is now firmly established.  This is a consequence of ever-increasing 
computing power and, more importantly, recent developments in measurement 
technologies which have enabled laboratory experiments to measure accurately the 
concentrations of the agent and other active metabolites.  Mathematical models that 
have been developed independently of biological experiments are often too complex 
and lack validation for any real practical purpose. 
In the present paper, the development of a mathematical model which 
describes the in vitro kinetics of the anti-cancer agent topotecan (TPT) on human 
osteosarcoma cells is described.  Clinical evidence for the cytotoxic properties of 
topotecan (TPT) against lung, breast and ovarian cancers is well known [1].  TPT is a 
water-soluble derivative of camptothecin, which is an alkaloid isolated from a 
Chinese tree, Camptotheca acuminata.  TPT acts as an inhibitor of topoisomerase-I 
[2], which is a nuclear enzyme involved in DNA replication and transcription.  The 
enzyme unwinds supercoiled double-stranded DNA (dsDNA) by temporarily binding 
to and cleaving the strands, forming a cleavable complex.  This process is tightly 
controlled and barely detectable.  The cleavage is then coupled with religation to 
check and then restore the strands to form the original DNA complex.  In the presence 
of TPT, the cleaved DNA-topoisomerase-I complex is stabilised, effectively 
inhibiting religation.  As DNA replication continues the TPT-induced double-strand 
breaks that have formed prevent any further cell growth. 
Part of the overall model was developed earlier to describe the 
pharmacokinetics (PK) of TPT [3]; this provides a description of the activity of TPT 
and the subsequent delivery of the active form to the nuclear DNA target.  In the 
 2
present paper, the linking of this part of the model into another part describing the 
growth of cells is discussed.  This new component, the pharmacodynamic (PD) part of 
the overall model, is based on the cell cycle model of Tyson and Novak [4].  The 
objective of the overall model is to show the dynamic interaction of the drug with its 
molecular target, and its impact on cell growth. 
The model described in the present paper has been validated with specific live-
cell experimental data from the Wales College of Medicine, where quantitative 
laboratory assays have been developed that enable single cell events to be tracked and 
measured with time [5].  These data are used to validate and search for cellular routes 
of the evasion of the drug, i.e. drug resistance.  Ultimately, the aim of the model is to 
design and predict the consequences of tailored drug treatments for individuals.  With 
this in mind, care has been taken to develop a highly flexible model, which is capable 
of predicting cell response pathways for use in drug discovery. 
The layout of the remainder of this paper is as follows:  Section 2 introduces 
the PK model, while Section 3 introduces the PD model; Section 4 discusses the 
linking of the two models, and Section 5 describes how well the PK-PD model 
predicts the experimental behaviour. 
 
2. The Pharmacokinetic (PK) Model 
 
The PK model [3], which is shown in Figure 1, is compartmental, with three regions: 
• The MEDIUM, into which TPT is added; 
• The EXTRACELLULAR region, from which TPT can enter the cells; 
• The CELLULAR region, which is further divided into the CYTOPLASM and 
the NUCLEUS. 
The model describes the chemical reactions that occur when the drug moves from the 
medium to the cellular regions and the nucleus.  Under physiological conditions TPT 
is able to change its chemical structure, from an active (closed-ring, lactone) form 
(TPT-L) to an inactive (open-ring, hydroxyl acid) form (TPT-H); this is a reversible 
reaction.  Both TPT-L and TPT-H exist in the medium, the extracellular region and 
the cytoplasm, but it is assumed that only TPT-L exists in the nucleus [3]. 
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 The model is described by the following system of Ordinary Differential 
Equations:- 
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The subscripts m, e, c and n, denote the medium, extracellular region, 
cytoplasm and nucleus, respectively, with the volumes of the compartments denoting 
these regions being Vm, Ve, Vc and Vn.  In the equations, v0, v1 and v2 are volume ratios 
given by v0 = Ve/Vm, v1 = Ve/Vc and v2 = Vn/Vc.  As noted above, it is assumed that all 
drug in the nucleus is bound and that only TPT-L binds to DNA. In all other locations 
reversible hydrolysis occurs and is modelled as a two-compartment sub-model; for 
example, the rate constants kom and kcm define the ring opening (for TPT-L) and ring 
closing (for TPT-H) respectively in the medium.  The mixing between the medium 
and extracellular region is modelled by first-order flows, with kmi being the rate 
constant for the flow into the extracellular region from the medium and kmo being the 
rate constant for the flow in the opposite direction.  The flow across the plasma 
membrane between the extracellular region and the cytoplasm is assumed to be for 
TPT-L only [6], and is again modelled by first-order flows. 
The rate at which TPT-L binds to DNA is assumed to be proportional to the 
product of the concentration of TPT-L in the cytoplasm, Lc(t), and the free 
concentration of binding sites BBF(t) (in accordance with the Law of Mass Action).  
The concentration of free sites is given by: BFB (t) = BBT − Ln(t), where Ln is the 
concentration of bound drug.  Dissociation of bound drug is assumed to be first order, 
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yielding either cytosolic TPT-L (with rate constant kdl) or TPT-H (with rate constant 
kdh).  
 The drug is injected as a bolus of dose, D, at t = 0, yielding the initial 
conditions: Hm(0) = Le(0) = He(0) = Lc(0) = Hc(0) = Ln(0) = 0; and Lm(0) = (1+ν0)D.  
The non-zero initial condition accounts for the injection of drug into the medium 
before mixing with the extracellular region takes place.  Experimental measurements 
were of the concentrations of TPT-L and TPT-H (combined) in the extracellular 
region and the cytoplasm and of TPT-L in the nucleus.  With this input and these 
measurements, it was found that the model parameters were globally (uniquely) 
structurally identifiable [3].  The model parameters were then estimated from the data 
using the software package FACSIMILE [7], with good visual fits to the data and low 
residual sum of squared error obtained for almost all of the model parameters. 
 
3. The Pharmacodynamic (PD) Model 
 
The pharmacodynamic (PD) model is based on the cell cycle model of Tyson 
and Novak [4], shown in Figure 2.  The cell cycle comprises four phases (G1, S, G2, 
and M) where a single cell’s cellular machinery and chromosomes are replicated in 
order to undergo division [8].  In the first ‘gap’ or G1 phase, the chromosomes are 
unreplicated and the cell is prevented from entering cell division.  During transition 
from this phase to the Synthesis or S phase the cell receives a signal to commit to 
replication of the genetic material.  As new DNA is synthesised chromatids are 
duplicated in the S phase.  In the G2 phase, a cell prepares for commitment to mitosis 
(M).  In M, the nuclear material condenses, the nuclear membrane is lost, spindle 
fibres pull chromatids apart and a cleavage furrow forms, separating the two new 
daughters.  The newly formed daughter cells regain their nuclear membranes and de-
condense the nuclear material, establishing a new G1 state.  These processes are 
distinct and tightly regulated temporally and demand the spatial separation of the 
controlling molecules [9]. 
The cell cycle may be thought of as two alternative states, with G1 and S-G2-
M separated by Start and Finish transitions [4].  Start is defined as the time where cell 
replication begins and Finish where DNA replication is complete.  If there have been 
any problems, for example with DNA replication or chromosome alignment, the cell 
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cannot divide as the Finish transition cannot begin.  With this in mind, TPT is 
believed to be S phase specific as the cleavable complexes (representing the trapped 
drug-DNA topoisomerase complex) lead to dsDNA breaks by collision with actively 
replicating DNA.  This prevents further cell cycle progression.  It has been shown that 
many cells resist the effect of topotecan by failing to enter the S phase or replicate 
DNA during exposure [10].  By blocking entry to the S phase, it is possible to halt the 
growth of cells. 
 The cell cycle model of Figure 2 is regulated by the interaction of Cyclin 
dependent kinases (Cdk’s) and Cyclin B with a group of proteins called the Anaphase 
Promoting Complex (APC).  Cdk’s induce downstream processes by activating 
selected proteins, and the APC marks specific components to bring the cell cycle to an 
end.  The modified cell cycle model, which is the PD model used in this paper, is 
shown in Figure 3.  The heart of the model is the relationship between Cdk/Cyclin B 
and APC.  The principal model equations are: 
       ( )( )3 3 4
3 4
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where the components in square brackets are concentrations; the ki’s are rate 
constants; J3 and J4 are Michaelis-Menten constants; a is the size of the cell; is the 
maximum size of the cell; and g is the specific growth rate. 
*a
 
 
4.  The PK-PD Model 
 
As noted in Section 1, quantitative laboratory assays have been developed at 
the Wales College of Medicine that enable single cell events to be tracked and 
measured with time [5].  The cells in this application were human osteosarcoma cells, 
which had been engineered to carry a fluorescent reporter (an enhanced form of Green 
Fluorescent Protein eGFP) fused to cyclin B1, one of the master regulators of cell 
cycle progression.  The expectation was that the cyclin signature would show a 
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ramping up as cell progresses through the cell cycle and then betray their arrest or 
commitment to cell division.  The cells were treated with 0.01, 0.1, 1 or 10 μM of 
TPT for 1 hour at 37°C and then washed out.  Cultures were then incubated at 37°C 
over 48 hours, and during this time, they were tracked using a time-lapse digital 
camera to measure GFP fluorescence at high resolution every 20 minutes.  A mitotic 
event gave a large peak in the fluorescence time record, and it was found that the time 
between such events increased as TPT was added, from around 20 hours without TPT 
to around 36 hours with 10 μM of TPT.  This increase suggested coupling the PK 
model for TPT with the PD (cell cycle) model. Coupling a PK model with a PD 
model in this way is a relatively new idea [11].  A recent example [12] examined the 
effect that a lack of extracellular oxygen (hypoxia) would have on the growth of 
normal and cancerous cells. 
There is strong evidence [10] that the PK model should be coupled to the S-
phase of the PD model, so giving the combined PK-PD model shown in Figure 4.  
The transducer box in this figure indicates that the active TPT causes DNA damage 
that signals stress and sends an arrest signal to the Cdk/Cyclin complex master 
regulator.  This is considered to be an overall equilibrium – hence the forward and 
reverse arrows in the transducer box.  The principal PD model equations (8) and (10) 
remain the same, but there is now an additional term in Equation (9) for the input 
from the PK model: 
( )1 2 2 3d[ ] [ ] [ ] [d n
CdkCycB k k k APC k L CdkCycB
t
′ ′′ ′′= − − + + ]   .  (11) 
 
5. Comparison of Model Predictions and Experimental Data 
 
Figure 5 compares the measured data with the model predictions, in the 
absence of TPT (Figure 5A), and the presence of 1 μM and 10 μM of TPT (Figures 
5B and 5C, respectively).  The live cell data are denoted by the solid line and the 
model predictions by the dash-dot curve.  The Start and Finish cell cycle transitions 
can be identified easily and have been marked on Figure 5A.  Whilst the G2 phase is 
not clear, due to the low signal-to-noise ratio in the experimental data, it is possible to 
deduce the other phases.  As the cell divides, indicated by the spike, the growth of 
either one of its daughter cells can be monitored. 
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The model predictions present a very good approximation to the experiment.  
(The accuracy of the fits to the experimental data have been determined, in the first 
instance by calculating the least squares fit.  This resulted in r2 values of between 0.91 
and 0.95, which indicate a very good fit.)  The main outcome is that the model is 
capable of accurately predicting the time-event characteristics.  The model is also 
capable of predicting the Start and Finish transitions and the cell cycle phases.  This is 
partly a result of the fact that the parameter values are constantly changing from phase 
to phase and cell to cell.  It can be observed in Figures 5B and 5C that TPT extends 
the S phase and hence the overall time to mitosis. 
 
 
 
6.  Conclusions 
 
This paper has described the development of a PK-PD model describing the 
behaviour of human osteosarcoma cells with time.  The model is able to predict the 
effect that varying doses of topotecan have on cell growth, giving very good 
agreement with live-cell experimental data.  The model provides a framework to 
investigate the role of the signals from damaged DNA (i.e. originating from active 
drug delivered to critical sites as described by a PK model) to induce the arrest of cell 
cycle traverse by engaging aspects of the cell cycle machine.  It is this critical area 
that can be dysfunctional in a tumour cell to varying degrees and potentially 
accessible to modelling. 
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Figure 1: The Pharmacokinetic (PK) Model 
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Figure 2: The cell cycle model, after Tyson and Novak [4] 
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Figure 3: Modified Cell Cycle Model – the Pharmacodynamic (PD) Model 
 13
 14
 
Figure 4: The combined PK-PD Model 
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Figure 5: Variation of Cyclin B with time, (a) with no TPT, (b) with 1 μM of TPT and 
(c) with 10 μM of TPT. Solid line: experimental data; Dotted line: model prediction. 
 15
